← Leaderboards
Amanda M Schalk
Enzyme By Design, Inc.
$3,543,028
Attributed
$3,543,028
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,543,028 · 5
By mechanism
R44$1,993,539 · 1
R43$1,249,937 · 3
R41$299,552 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsAcute Myelocytic LeukemiaAsparaginePropertyPharmaceutical PreparationsEnzymesFda ApprovedToxic EffectBloodAsparaginaseGlutaminaseClinical TrialsEngineeringBiologicalPegaspargaseAcute Lymphocytic LeukemiaImmunologicsEscherichia ColiHalf-LifeIn VivoImmunogenicityCaviaAdult Acute Lymphocytic LeukemiaDose
Grant awards (8)
Engineering in vivo half-life extension of a novel mammalian asparaginase to increase feasibility of pan-cancer therapy$400,000
R43 · FY2024 · CA · contact PI
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy$836,804
R44 · FY2022 · CA · contact PI
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy$1
R44 · FY2021 · CA · contact PI
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy$1,156,734
R44 · FY2020 · CA · contact PI
Extending the in vivo half-life of a novel engineered mammalian asparaginase via its binding to human serum albumin$399,999
R43 · FY2020 · CA · contact PI
Maximizing the safety profile of a novel cancer therapeutic via the de-immunization of an engineered mammalian asparaginase$149,999
R43 · FY2020 · CA · contact PI
Maximizing the safety profile of a novel cancer therapeutic via the de-immunization of an engineered mammalian asparaginase$299,939
R43 · FY2019 · CA · contact PI
Development of a novel safe and efficacious biologic drug for the treatment of AML$299,552
R41 · FY2018 · CA · contact PI